Navigation Links
Juvenile Diabetes Research Foundation Names Monye Connolly Corporate Chair for its Annual Walk to Cure Diabetes
Date:3/4/2009

The 2009 Walk to Cure Diabetes will be held Saturday, October 17 at

Centennial Olympic Park

ATLANTA, March 4 /PRNewswire/ -- The Georgia Chapter of the Juvenile Diabetes Research Foundation (JDRF) has announced that Blue Cross and Blue Shield of Georgia (BCBSGa) President, Monye Connolly, will serve as the Corporate Chair for its annual, and largest, fundraising event, Walk to Cure Diabetes. The event is scheduled in Atlanta at Centennial Olympic Park on Saturday, Oct. 17, 2009.

Last year's walk raised more than $1.5 million to fund research to help find a cure for diabetes.

"The Juvenile Diabetes Research Foundation is firm in its commitment to finding a cure for diabetes and its complications through the support of research. BCBSGa truly believes in JDRF and its mission, which supports our mission of improving the lives of the people we serve and the health of our communities," said Connolly.

"We look forward to working with Monye Connolly in the months to come to make the 2009 Walk our best one ever. As someone with type 1 diabetes myself, it is very gratifying to have the support of such a large, successful company in our relentless goal to find a cure for diabetes and its complications," said Kris Bagwell, JDRF Georgia Board President

As many as 3 million people in the U.S. are now living with type 1 diabetes. Each year more than 15,000 children are diagnosed with diabetes - that's 40 children per day. More than 85 percent of JDRF's expenditures directly support research and research-related education.

Corporate sponsorships, corporate Walk Teams and Family Walk Teams will be the key to the success of the Walk to Cure Diabetes. For more information about JDRF, the critical research they fund and how you can help, call 404-420-5990, or visit www.jdrf.org.

About JDRF:

JDRF was founded in 1970 by the parents of children with type-1 diabetes - a disease that strikes children, adolescents and adults suddenly, making them insulin dependent for life, which carries the constant threat of devastating complications. Since inception, JDRF has provided more than $1.3 billion to diabetes research worldwide. More than 85 percent of JDRF's expenditures directly support research and research-related education. JDRF's mission is constant: to find a cure for diabetes and its complications through the support of research. To register now and participate, sponsor an event, build a walk team, or for more information, please visit www.jdrf.org, or call 404-420-5990.

About Blue Cross Blue Shield of Georgia:

Blue Cross and Blue Shield of Georgia, Inc. and Blue Cross and Blue Shield Healthcare Plan of Georgia, Inc. are independent licensees of the Blue Cross and Blue Shield Association(R) . The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Additional information about Blue Cross and Blue Shield of Georgia is available at www.bcbsga.com.


'/>"/>
SOURCE Juvenile Diabetes Research Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pennsylvanians May Donate Part of Tax Refund to Support Juvenile Diabetes Research
2. Etanercept, Methotrexate Safe for Juvenile RA
3. Second Annual Eye Ball Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology
4. University of South Florida receives new multimillion award to assess juvenile diabetes treatments
5. Drug May Ease Symptoms of Juvenile Arthritis
6. Pediatric researchers find possible master switch gene in juvenile arthritis
7. Early life infections increase the risk of rheumatoid arthritis and juvenile idiopathic arthritis
8. Specific mutations in the IL2RA gene associated with juvenile idiopathic arthritis
9. Chrysler LLC Vice Chairman and President Jim Press and His Wife Suwichada Serve as Honorary Co-Chairs of Annual Juvenile Diabetes Research Foundation Promise Ball
10. Study affirms effectiveness of medication for juvenile rheumatoid arthritis
11. Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... IsoComforter, Inc., one of ... the newly designed, innovative shoulder wrap. The newly designed shoulder wrap has ... injured arm and shoulder to promote faster healing. It is highly recommended for ...
(Date:2/9/2016)... ... 09, 2016 , ... United Methodist Communications collaborated with Chocolate ... animated video designed to prevent the next widespread Ebola outbreak from ... being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and other African ...
(Date:2/9/2016)... ... February 09, 2016 , ... i2i Systems, an early innovator and ... data vendors in the latest KLAS report, Population Health Management 2015: How Far Can ... market for population health management (PHM). The latest KLAS Report, leveraging over 200 ...
(Date:2/9/2016)... Ashburn, VA (PRWEB) , ... February 09, 2016 ... ... ) Small Mammal Prize has officially been won. A team from 21st Century ... has discovered a way to preserve the delicate neural circuits of an intact ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... redesigned website, federallabs.org . The site houses a wealth of federal resources ... technologies through the process called technology transfer (T2). As a network of over ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... disease and heart failure, today announced that it intends to ... stock in an underwritten public offering.  The offering is subject ... assurance as to whether or when the offering may be ... the offering.   --> --> ...
(Date:2/9/2016)... 9, 2016 The new report "Global Diagnostic Ultrasound Devices ... Consulting group reveals that global diagnostic ultrasound devices market was valued ... US$ 7,466.3 million by 2019 at a CAGR of 6.8% from ... ultrasound market has been analyzed for six geographies of ... Asia-Pacific , Latin America , ...
(Date:2/9/2016)... , Feb. 9, 2016 The leader ... that AcceleDent ® is the recipient of the ... category. An FDA-cleared, Class II medical device that speeds ... percent and relieves pain often associated with treatment, AcceleDent ... participated in the annual Orthotown survey of ...
Breaking Medicine Technology: